REZOLUTE INC. - COMMON STOCK (NV)

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

07 نوفمبر 2024 16:05:02 بحسب Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

05 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

19 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

09 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

27 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

05 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

31 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

27 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

24 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

13 يونيو 2024 23:30:00 بحسب Nasdaq GlobeNewswire

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

13 يونيو 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rezolute to Participate in the Jefferies Global Healthcare Conference

30 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

21 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

15 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

23 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

06 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

24 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

23 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

14 ديسمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire